Background {#Sec1}
==========

Squamous cell carcinoma (SCC) of the anal canal (AC) is an uncommon tumour with an increasing incidence \[[@CR1]--[@CR3]\]. The treatment standard is organ sparing chemo-radiotherapy (CRT) \[[@CR4], [@CR5]\], which achieves loco-regional control in 63--86% \[[@CR6]--[@CR8]\] of patients but carries a risk of significant acute and late toxicity \[[@CR9]\].

In RTOG 0529, Intensity Modulated Radiotherapy (IMRT) was shown to reduce acute toxicity and cause fewer treatment interruptions compared with historical controls \[[@CR10]\]. It also highlighted the increased complexity of IMRT. Remarkably, 81% of plans required revision and 46% required multiple revisions. Despite the provision of a contouring atlas, most revisions were required for incorrect contouring.

Contouring errors in IMRT based CRT increase loco-regional recurrence in head and neck SCC \[[@CR11], [@CR12]\]. This raises concerns for AC patients treated with IMRT by inexperienced clinicians. Indeed, population based data suggests AC patients treated at high volume centres have improved survival \[[@CR13]\].

The Trans-Tasman Radiation Oncology Group (TROG) investigated IMRT as a new technology in the treatment of AC as part of their Assessment of New Radiation Oncology Technology and Treatments (ANROTAT) \[[@CR14]\]. Their study compared the safety, clinical efficacy and cost effectiveness of IMRT with three-dimensional conformal radiation therapy (3DCRT).

The credentialing component of this study involved a benchmarking assessment performed by nine Australian centres. Each centre was provided a computed tomography (CT) dataset of a female patient with T3 N2 AC (primary greater than 50 mm with involved mesorectal and inguinal lymph nodes \[LN\]) to be treated with 54Gy in 30 fractions. Centres were asked to contour clinical target volumes (CTV) and organs at risk (OAR).

Having acquired these contours from TROG, we sought to describe CTV and OAR contour variability as well as model the impact of contour variation on tumour control probability (TCP) when using IMRT for AC.

Methods {#Sec2}
=======

Treatment planning {#Sec3}
------------------

Each of the nine Australian centres participating in the TROG TRP11.A (ANROTAT) Study B contoured OAR and CTVs using a standard protocol (Table [1](#Tab1){ref-type="table"}) and the Australian Gastrointestinal Trials Group (AGITG) contouring atlas \[[@CR15]\].Table 1Tumour and organ at risk contoured volumesTumour VolumesOrgans at RiskPrimary clinical target volume to receive 54Gy (CTV54p)Small bowelNodal clinical targe volume to receive 54Gy (CTV54n)BladderElective clinical target volume to receive 45Gy (CTV45)External genitaliaNote: CTV45 included mesorectal, pre-sacral, internal iliac, external iliac, obturator and inguinal lymph nodesHead and neck of femur\
Bone marrow (ilium)

Varian's Eclipse treatment planning system was used to generate nine representative IMRT plans. An optimised template-based IMRT planning protocol was initially applied to each contour set. If dosimetric parameters were not met in all plans, the template was adjusted and re-applied to all plans until all target volume and OAR constraints were met. Planning Target Volume (PTV) coverage requirements and OAR constraints were based on ANROTAT guidelines ([Appendix](#App1){ref-type="app"}).

Geometric analysis {#Sec4}
------------------

All observer generated contours were collated on a single copy of the benchmarking CT dataset. A reference contour was generated using the STAPLE \[[@CR16]\] algorithm in the Computational Environment for Radiotherapy Research (CERR) \[[@CR17]\]. In-house code was used to analyse the geometric variation in contours. Metrics of comparison included two volume overlap indices; concordance index (CI) and dice similarity coefficient (DSC).

Tumour control probability {#Sec5}
--------------------------

Dose volume histogram (DVH) data was extracted from the treatment plans using CERR \[[@CR17]\] and Matlab (The Mathworks, Natick, USA). From the DVHs, CompPlan \[[@CR18]\] (open source software) calculated a TCP for each plan using a linear quadratic and logitEUD model (shown in Figs. [1](#Fig1){ref-type="fig"} and [2](#Fig2){ref-type="fig"}). The models included a fraction-size effect correction.Fig. 1The linear quadratic modelFig. 2The logitEUD model

For the linear quadratic model where n is the number of fractions and D' is the total dose, an α/β ratio of 10Gy, α of 0.196 and N~0~ (number of initial clonogens) of 34,900 were used \[[@CR19]\]. A sensitivity analysis investigated the effect on TCP of increasing N~0~ and decreasing prescription dose.

For the logitEUD model where v~i~ is a voxel, γ~50~ is the slope of the dose response curve at D~50~ and D~i~ is the total dose delivered to each voxel, D~50~ values (dose required for a 50% probability of tumor control at 2 years) for gross and microscopic disease were 42Gy and 30Gy, respectively \[[@CR19]\]. Given these values were taken from curves fit to patients treated with CRT, the effect of concurrent chemotherapy was implicitly incorporated.

Results {#Sec6}
=======

Geometric analysis {#Sec7}
------------------

Table [2](#Tab2){ref-type="table"} shows the results of the OAR geometric analysis. There was close contour agreement for the bladder (median concordance index \[CI\] 0.94), head and neck of femur (CI 0.88) and bone marrow (CI 0.84). Greater contour variation was seen in the small bowel (CI 0.65) and external genitalia (CI 0.65).Table 2Organ at risk geometric analysisOrgans at RiskStatsCIDSCVolume (cm3)Small bowelMedian0.650.79543.22Range0.120.10132.37BladderMedian0.940.97156.37SD0.010.016.43External genitaliaMedian0.650.79130.61SD0.190.1765.47Head and neck of femurMedian0.880.93202.29SD0.060.0323.73Bone marrow (ilium)Median0.840.91371.61SD0.060.0322.62*SD*: standard deviation, *CI*: concordance index, *DSC*: dice similarity coefficient

Table [3](#Tab3){ref-type="table"} shows the results of the tumour volume geometric analysis. Increasing contour variation was seen in CTV54n (CI 0.85), CTV54p (CI 0.77) and CTV45 (CI 0.71), respectively. The CTV45 and CTV54p contours are shown in Fig. [3](#Fig3){ref-type="fig"}.Table 3Tumour control probability and tumour volume geometric analysisVolumeStatsTCP (LQ)TCP (Logit)CIDSCVolume (cm3)CTV45Median0.840.600.710.821299.38SD0.180.040.130.10190.64CTV54pMedian0.940.520.770.86458.83SD0.110.020.170.13132.92CTV54nMedian1.000.530.850.8937.92SD0.000.020.260.217.69*CTV45*: elective clinical targe volume, *CTV54p*: primary clinical target volume, *CTV54n*: nodal clinical target volume, *SD*: standard deviation, *CI*: concordance index, *DSC*: dice similarity coefficientFig. 3Tumour volumes contoured by the nine participating centres. Left: Primary clinical target volumes (CTV54p), Right: Elective clinical targe volumes (CTV45)

Tumour control probability {#Sec8}
--------------------------

The TCP for CTVs are shown in Table [3](#Tab3){ref-type="table"}. Using the linear quadratic model, the median TCP for CTV45, CTV54p and CTV54n was 0.84 (standard deviation \[SD\] 0.18), 0.94 (SD 0.11) and 1.00 (SD 0.00), respectively. Using the logitEUD model, the median TCP for CTV45, CTV54p and CTV54n was 0.60 (SD 0.04), 0.52 (SD 0.02) and 0.53 (SD 0.02).

Sensitivity analysis of the linear quadratic model revealed that the TCP reduced as tumour cell load increased (Fig. [4a](#Fig4){ref-type="fig"}) but variation in TCP between plans increased (Fig. [4b](#Fig4){ref-type="fig"}). Likewise, as radiation dose decreased, TCP reduced (Fig. [4c](#Fig4){ref-type="fig"}) and variation in TCP between plans increased (Fig. [4d](#Fig4){ref-type="fig"}).Fig. 4Sensitivity analyses. **a**: Tumour control probability with changing N~0~, **b**: variation in tumour control probability between plans with changing N~0~, **c**: tumour control probability with changing dose, **d**: variation in tumour control probability between plans with changing dose. TCP = Tumour Control Probability, SD = Standard Deviation, N~0~ = number of initial clonogens, Gy = Gray, CTV54p = Primary clinical target volume to receive 54Gy, CTV54n = Nodal clinical targe volume to receive 54Gy, CTV45 = Elective clinical target volume to receive 45Gy

Discussion {#Sec9}
==========

Organ at risk contour variation {#Sec10}
-------------------------------

Our results reveal while there was good inter-observer agreement for the bladder (CI: 0.94), head and neck of femur (CI 0.88) and bone marrow (CI: 0.84), there was significant contour variation in the small bowel (CI 0.65) and external genitalia (CI: 0.65).

For the small bowel, inclusion of the large bowel, iliac vessels, ovaries, peritoneum and muscle were common contouring errors. The lack of oral contrast may have contributed to these inaccuracies. Oral contrast delivered 1 h prior to CT simulation is usually recommended to improve small bowel identification \[[@CR20]\].

Controversy persists regarding the optimal bowel contouring technique. No consensus was reached by RTOG \[[@CR20]\] and QUANTEC \[[@CR21]\] list dose constraints for both bowel loops and a bowel bag. While a bowel bag accounts for the mobility of viscera and simplifies OAR contouring, it may have limitations for post-surgical patients and in capturing inferior motion \[[@CR22]\].

Misidentification of the small (60%) and large (45%) bowel was also common in plans submitted to RTOG 0529 \[[@CR23]\]. However, accuracy of the external genitalia contours was not reported. In fact the RTOG pelvic OAR contouring guidelines do not include instructions for contouring external genitalia \[[@CR20]\] and no consensus guidelines exist. While United Kingdom guidelines have been proposed \[[@CR24]\], until consensus guidelines are formalised, variation in external genitalia contours is likely to persist.

For the development and implementation of evidenced based OAR dose constraints, consistent contouring is imperative \[[@CR25], [@CR26]\]. This is particularly true in AC IMRT where the proximity of OAR and tumour volumes often requires a compromise between adequate coverage and safety.

Tumour volume contour variation {#Sec11}
-------------------------------

Despite being provided gross tumour volumes (GTV), variations in the protocoled CTV expansions were seen: CTV54p (CI 0.77), CTV54n (CI 0.85) and CTV45 (CI 0.71). Unsurprisingly, the greatest variation was seen in the CTV45 volumes. These are the largest and the least influenced by the GTV. Incorrect elective nodal contouring was also common in RTOG 0529 where errors were seen in the mesorectum (55%), pre-sacral (43%), inguinal (33%) and iliac nodal groups (31%).

The greatest discrepancies in the CTV45 volumes were in the anterior direction with variable expansion into the uterus and bladder. The AGITG guidelines recommend an internal margin expansion of 1 cm into the bladder and uterus to account for bladder volume variation \[[@CR15]\].

The greatest discrepancies in the CTV54p volumes were also in the anterior direction with variable expansion into the vagina and genitalia. Some have highlighted the risk of genital relapse when IMRT is used to achieve genital sparing \[[@CR27]\]. While this has been challenged more recently \[[@CR28]\], we emphasise the priority of adequate tumour coverage over genital sparing and stress the importance of accurate multi-modality baseline imaging to help optimally define the extent of disease.

Contouring atlases for anorectal volumes have been shown to reduce inter-observer variability \[[@CR29]\], however, atlases were available to observers in both the RTOG and TROG studies. Perhaps this variation can be attributed to clinicians coming to terms with a new technique.

A literature review identified guidelines, teaching, auto-contouring and multi-modality imaging as interventions that reduce inter-observer variability in contour delineation \[[@CR30]\]. Online teaching and contouring workshops are now offered by international cancer societies and clinicians can have their volumes peer reviewed at their centre and through participation in clinical trials incorporating radiotherapy quality assurance.

Tumour control probability {#Sec12}
--------------------------

IMRT is the treatment of choice for AC \[[@CR31]\]. It enhances the therapeutic window by reducing dose to OAR and resultant acute toxicity \[[@CR23]\]. Fewer treatment breaks for toxicity are required and it offers the prospect of safe dose escalation for large tumours. However, AC contouring is complex and considerable variation exists in target volume delineation \[[@CR29], [@CR31]\].

We have shown that minor contour variations generated from a common protocol do not translate into significant differences in TCP. By applying a template-based IMRT planning protocol, we isolated the impact of contour variation on TCP. Further TCP variability would be expected should centres develop their own treatment plans or employ different treatment doses.

Contours for this study were generated from a common contouring guideline \[[@CR14]\]. Contouring guidelines lead to greater inter-observer agreement \[[@CR32]\] and the provision of an anorectal contouring atlas has been shown to increase TCP and reduce normal tissue complication probability (NTCP) \[[@CR29]\].

GTV contours were supplied in the TROG study which may have reduced CTV variation. Inaccurate GTV delineation occurred in 21% of plans submitted to RTOG 0529 \[[@CR23]\]. Target volume delineation is more accurate with the use of co-registered Positron Emission Tomography (PET) and Magnetic Resonance Imaging (MRI) and is recommended for treatment planning \[[@CR31]\]. PET is recommended to identify lymph nodes requiring inclusion in the GTV \[[@CR33]\].

Sensitivity analysis {#Sec13}
--------------------

We investigated the influence of prescription dose and N~0~ (number of initial clonogens) on the TCP predicted by the linear quadratic model. Increasing N~0~ led to a reduction in TCP (Fig. [4a](#Fig4){ref-type="fig"}) and an increase in the TCP variation between plans (Fig. [4b](#Fig4){ref-type="fig"}). Decreasing dose led to a reduction in TCP (Fig. [4c](#Fig4){ref-type="fig"}) and increase in TCP variation between plans (Fig. [4d](#Fig4){ref-type="fig"}).

While the influence of dose and N~0~ on the absolute TCP is not surprising, the effect on TCP variation is quite interesting. It suggests contour variations become more critical as one moves down the dose response curve either by increasing tumour cell load or reducing dose. These are important insights for radiation dose de-escalation trials such as ACT 3 and 4 \[[@CR34]\] and highlights the central role real-time radiotherapy quality assurance should play in these studies.

Limitations and future directions {#Sec14}
---------------------------------

In radiation therapy, TCP models have traditionally been limited to the relative comparison of treatment plans rather than their absolute predictive power. Indeed, the difference in tumour control estimated by the two models used in our study highlights the dangers of over interpreting TCP results or using them to inform radiotherapy dose selection.

That contours were completed in the context of a trial using a common protocol with a GTV already provided is a shortcoming of this study potentially limiting its applicability to the wider community. Our results are likely to underestimate contour variation and do not capture the effect of radiotherapy plan generation.

Our study aim was to isolate the impact of contour variation on TCP. While we appreciate there is manual bias in planning \[[@CR35]\], it is out of the scope of this study. We tried to mitigate against this by using a single planner and single patient anatomy, deploying a class solution beam arrangement, objectives and priorities.

While a NTCP assessment was explored, this was abandoned due to a lack of reliable radiobiological parameters in the literature. The principle benefit of IMRT is reduced OAR dose, avoidance of toxicity induced treatment gaps and the prospect of safe dose escalation for larger tumours. To achieve this, tumour volumes must balance adequate coverage of at risk sites with toxicity risk.

The ACT 3--5 \[[@CR34]\] studies will provide valuable insights into the radiation dose response curve for AC. The incorporation of prognostic factors other than stage such as human papilloma virus status could help further refine this relationship \[[@CR36]\]. Treatment adaptation represents another promising approach and may ultimately provide the best means of individualising treatment \[[@CR37]\].

Conclusions {#Sec15}
===========

In the context of a clinical study, with the dose and parameters used, minor contour variations generated from a common guideline did not significantly impact TCP. With increasing tumour cell load or reducing RT dose, contour variations may be more critical.

Appendix {#Sec16}
========

VolumeConstraintPTV 45D95 ≥ 40.5GyD98 ≥ 36GyD98 ≥ 36GyPTV 54D95 ≥ 48.6D98 ≥ 43.2GyD2% ≤ 62.1GySmall bowelV30Gy ≤ 200 cm^3^V35Gy ≤ 150 cm^3^V45Gy ≤ 20 cm^3^V50Gy = 0 cm^3^Femoral headsV30Gy ≤ 50%V40Gy ≤ 35%V44Gy ≤ 5%Iliac crestV30Gy ≤ 50%V40Gy ≤ 35%V50Gy ≤ 5%External genitaliaV20Gy ≤ 50%V30Gy ≤ 35%V40Gy ≤ 5%BladderV35Gy ≤ 50%V40Gy ≤ 35%V50Gy ≤ 5%

3DCRT

:   Three-dimensional conformal radiation therapy

AC

:   Anal cancer

AGITG

:   Australian Gastrointestinal Trials Group

ANROTAT

:   Assessment of New Radiation Oncology Technology and Treatments

CERR

:   Computational Environment for Radiotherapy Research

CI

:   Concordance Index

CRT

:   Chemo-radiotherapy

CT

:   Computed tomography

CTV

:   Clinical target volume

CTV45

:   Elective clinical target volume to receive 45Gy

CTV54n

:   Nodal clinical target volume to receive 54Gy

CTV54p

:   Primary clinical target volume to receive 54Gy

DSC

:   Dice similarity coefficient,

DVH

:   Dose Volume Histogram

GTV

:   Gross tumour volumes,

IMRT

:   Intensity modulated radiotherapy

LN

:   Lymph node

MRI

:   Magnetic Resonance Imaging

OAR

:   Organs at risk

PET

:   Positron Emission Tomography

PTV

:   Planning Target Volume

SCC

:   Squamous cell carcinoma

SD

:   Standard Deviation

TCP

:   Tumour Control Probability

TROG

:   Trans-Tasman Radiation Oncology Group
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